Skip to main content

Table 1 Effect of kainate treatment on motoneuron viability in the absence or presence of EPO derivatives.

From: Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo

Motoneuron survival (% of controls)
(No. replicates) Without cytokine With cytokine
ASIALO-EPO (12) 58 ± 11 91 ± 12a
CEPO (15) 42 ± 12 67 ± 19b
  1. Viability of SMI 32-positive motoneurons in mixed neuron/glia cultures after 48-h incubation with kainate (5 µM). When present, cytokines (100 ng/mL) were added to motoneuron cultures 3 days before treatment and re-added with the glutamate agonist. Data represent mean ± SD. For both ASIALO-EPO and CEPO, fint P < 0.001. aP < 0.001, bP > 0.01, different from control motoneurons, 2-way ANOVA and Tukey’s test.